{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:13:47Z","timestamp":1781712827609,"version":"3.54.5"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82000195"],"award-info":[{"award-number":["82000195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2022M721981"],"award-info":[{"award-number":["2022M721981"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taishan Scholars Program of Shandong Province","award":["tsqn201909184"],"award-info":[{"award-number":["tsqn201909184"]}]},{"name":"Shandong Provincial Health Construction Program of Medical Science and Technology Innovation Team"},{"name":"Academic Promotion Programme of Shandong First Medical University","award":["2020RC007"],"award-info":[{"award-number":["2020RC007"]}]},{"name":"Research Promotion Program of Shandong Provincial Hospital"},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2024MH050, ZR2020QH094"],"award-info":[{"award-number":["ZR2024MH050, ZR2020QH094"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood, bone marrow, spleen, and lymph nodes. The associated immune dysregulation predisposes CLL patients to a higher risk of secondary malignancies and infections, which significantly contribute to morbidity and mortality rates. The advent of immunotherapy has revolutionized the prognosis of CLL, advancing treatment modalities and offering substantial benefits to patient outcomes. This review endeavors to synthesize and scrutinize the efficacy, merits, and limitations of the current immunotherapeutic strategies for CLL. The aim is to inform the selection of optimal treatment regimens tailored to individual patient needs. Furthermore, the review juxtaposes various therapeutic combinations to elucidate the comparative advantages of each approach, with the ultimate objective of enhancing patient prognosis and quality of life.<\/jats:p>","DOI":"10.1186\/s40164-025-00644-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:22:07Z","timestamp":1744273327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy in chronic lymphocytic leukemia: advances and challenges"],"prefix":"10.1186","volume":"14","author":[{"given":"Pan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391:1524\u201337.","journal-title":"Lancet"},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-022-00423-y","volume":"10","author":"X Zhang","year":"2022","unstructured":"Zhang X, Han Y, Hu X, Wang H, Tian Z, Zhang Y, et al. Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model. Biomark Res. 2022;10:75.","journal-title":"Biomark Res"},{"issue":"Suppl 1","key":"644_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/annonc\/8.suppl_1.S93","volume":"8","author":"E Montserrat","year":"1997","unstructured":"Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 1997;8(Suppl 1):93\u2013101.","journal-title":"Ann Oncol"},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 2","key":"644_CR5","first-page":"S11","volume":"97","author":"JA Woyach","year":"2022","unstructured":"Woyach JA. Management of relapsed\/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(Suppl 2):S11\u20138.","journal-title":"Am J Hematol"},{"key":"644_CR6","doi-asserted-by":"crossref","unstructured":"Cheson BD, Sharman JP. Current approaches and novel new agents in the treatment of chronic lymphocytic leukemia. JCO Oncol Pract. 2024;OP2300770.","DOI":"10.1200\/OP.23.00770"},{"key":"644_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-024-01001-1","volume":"14","author":"R Bennett","year":"2024","unstructured":"Bennett R, Seymour JF. Update on the management of relapsed\/refractory chronic lymphocytic leukemia. Blood Cancer J. 2024;14:33.","journal-title":"Blood Cancer J"},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/cancers16071290","volume":"16","author":"A Visentin","year":"2024","unstructured":"Visentin A, Frazzetto S, Trentin L, Chiarenza A. Innovative combinations, cellular therapies and bispecific antibodies for chronic lymphocytic leukemia: A narrative review. Cancers (Basel). 2024;16:1290.","journal-title":"Cancers (Basel)"},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003495-200363120-00003","volume":"63","author":"JE Frampton","year":"2003","unstructured":"Frampton JE, Wagstaff AJ, Alemtuzumab. Drugs. 2003;63:1229\u201343. discussion 1245\u20131246.","journal-title":"Drugs"},{"issue":"Suppl 7","key":"644_CR10","doi-asserted-by":"publisher","first-page":"vii154","DOI":"10.1093\/annonc\/mdq373","volume":"21","author":"M Hallek","year":"2010","unstructured":"Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010;21(Suppl 7):vii154\u2013164.","journal-title":"Ann Oncol"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Roug\u00e9","year":"2020","unstructured":"Roug\u00e9 L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367:1224\u201330.","journal-title":"Science"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2\u20139.","journal-title":"Semin Oncol"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1073\/pnas.85.1.208","volume":"85","author":"TF Tedder","year":"1988","unstructured":"Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A. 1988;85:208\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"644_CR14","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359\u201368.","journal-title":"Oncogene"},{"key":"644_CR15","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793\u2013800.","journal-title":"Blood"},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5:564\u201376.","journal-title":"Nat Rev Drug Discov"},{"key":"644_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1756-8722-2-29","volume":"2","author":"KJ Maddocks","year":"2009","unstructured":"Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol. 2009;2:29.","journal-title":"J Hematol Oncol"},{"key":"644_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1634\/theoncologist.2017-0150","volume":"23","author":"JR Brown","year":"2018","unstructured":"Brown JR, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A. The role of rituximab in chronic lymphocytic leukemia treatment and the potential utility of biosimilars. Oncologist. 2018;23:288\u201396.","journal-title":"Oncologist"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ctrv.2010.11.005","volume":"37","author":"KS Saini","year":"2011","unstructured":"Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, et al. Rituximab in hodgkin lymphoma: is the target always a hit? Cancer Treat Rev. 2011;37:385\u201390.","journal-title":"Cancer Treat Rev"},{"key":"644_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"644_CR21","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trn\u011bn\u00fd M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A phase 2\/3 multicenter, randomized, Open-Label study to compare the efficacy and safety of Lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-Cell lymphoma. Clin Cancer Res. 2017;23:4127\u201337.","journal-title":"Clin Cancer Res"},{"key":"644_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-6-36","volume":"6","author":"M Wu","year":"2013","unstructured":"Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol. 2013;6:36.","journal-title":"J Hematol Oncol"},{"key":"644_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","volume":"115","author":"JC Byrd","year":"2010","unstructured":"Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010;115:489\u201395.","journal-title":"Blood"},{"key":"644_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Clinical practice: herpes Zoster. N Engl J Med. 2013;369:255\u201363.","journal-title":"N Engl J Med"},{"key":"644_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","volume":"10","author":"G Wei","year":"2017","unstructured":"Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10:150.","journal-title":"J Hematol Oncol"},{"key":"644_CR26","doi-asserted-by":"publisher","first-page":"e1428158","DOI":"10.1080\/2162402X.2018.1428158","volume":"7","author":"S Elias","year":"2018","unstructured":"Elias S, Kahlon S, Kotzur R, Kaynan N, Mandelboim O. Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). Oncoimmunology. 2018;7:e1428158.","journal-title":"Oncoimmunology"},{"key":"644_CR27","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122:3482\u201391.","journal-title":"Blood"},{"key":"644_CR28","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-C\u00e9ligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912\u20139.","journal-title":"J Clin Oncol"},{"key":"644_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","volume":"99","author":"U Randen","year":"2014","unstructured":"Randen U, Tr\u00f8en G, Tierens A, Steen C, Warsame A, Beiske K, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99:497\u2013504.","journal-title":"Haematologica"},{"key":"644_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352.","journal-title":"Lancet Oncol"},{"key":"644_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"},{"key":"644_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"644_CR33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328.","journal-title":"N Engl J Med"},{"key":"644_CR34","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S2352-3026(16)30187-9","volume":"4","author":"A Lipsky","year":"2017","unstructured":"Lipsky A, Martin P. Bendamustine-rituximab in mantle cell lymphoma. Lancet Haematol. 2017;4:e2\u20133.","journal-title":"Lancet Haematol"},{"key":"644_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323\u201332.","journal-title":"N Engl J Med"},{"key":"644_CR36","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with Bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928\u201342.","journal-title":"Lancet Oncol"},{"key":"644_CR37","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-Year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042\u201354.","journal-title":"J Clin Oncol"},{"key":"644_CR38","first-page":"2628","volume":"136","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without Bendamustine vs Bendamustine-rituximab in relapsed\/refractory follicular lymphoma. Blood. 2020;136:2628\u201337.","journal-title":"Blood"},{"key":"644_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood.2023020554","volume":"143","author":"D Papazoglou","year":"2024","unstructured":"Papazoglou D, Wang XV, Shanafelt TD, Lesnick CE, Ioannou N, De Rossi G, et al. Ibrutinib-based therapy reinvigorates CD8\u2009+\u2009T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 2024;143:57\u201363.","journal-title":"Blood"},{"key":"644_CR40","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-Cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther. 2017;34:2232\u201373.","journal-title":"Adv Ther"},{"key":"644_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood. 2003;101:6\u201314.","journal-title":"Blood"},{"key":"644_CR42","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJM200303273481316","volume":"348","author":"PA James","year":"2003","unstructured":"James PA, Hartz AJ, Levy BT. Specialty of ambulatory care physicians and mortality after myocardial infarction. N Engl J Med. 2003;348:1288\u20139. author reply 1288\u20131289.","journal-title":"N Engl J Med"},{"key":"644_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M, Chronic Lymphocytic L. 2025 Update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100:450\u201380.","journal-title":"Am J Hematol"},{"key":"644_CR44","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135\u201343.","journal-title":"J Clin Oncol"},{"key":"644_CR45","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"644_CR46","first-page":"1672","volume":"90","author":"AP Ng","year":"2005","unstructured":"Ng AP, Worth L, Chen L, Seymour JF, Prince HM, Slavin M, et al. Cytomegalovirus dnaemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica. 2005;90:1672\u20139.","journal-title":"Haematologica"},{"key":"644_CR47","doi-asserted-by":"crossref","unstructured":"Thouenon R, Verdeil G. Tumor microenvironment squeezes out the juice from T cells. Cell Res. 2024;34(10):677-678.","DOI":"10.1038\/s41422-024-00987-4"},{"key":"644_CR48","doi-asserted-by":"crossref","unstructured":"Arseni L, Sigismondo G, Yazdanparast H, et al. Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. Nat Commun. 2025;16(1):1041.","DOI":"10.1038\/s41467-025-56318-7"},{"key":"644_CR49","doi-asserted-by":"crossref","unstructured":"Knickmeier C, Noubissi Nzeteu GA, Gibbs BF, et al. It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. Front Immunol. 2025;16:1495907.","DOI":"10.3389\/fimmu.2025.1495907"},{"key":"644_CR50","doi-asserted-by":"crossref","unstructured":"Zhao X, Liu B, William WN, et al. Interferon-\u03b5 loss is elusive 9p21 link to immune-cold tumors, resistant to immune-checkpoint therapy and endogenous CXCL9\/10 induction. J Thorac Oncol. 2024.","DOI":"10.1016\/j.jtho.2024.12.020"},{"key":"644_CR51","doi-asserted-by":"crossref","unstructured":"Floudas CS, Goswami M, Donahue RN, Pastor DM, Redman JM, Brownell I et al. Novel combination immunotherapy and clinical activity in patients with HPV-Associated cancers: A nonrandomized clinical trial. JAMA Oncol. 2025.","DOI":"10.1001\/jamaoncol.2024.6998"},{"key":"644_CR52","doi-asserted-by":"crossref","unstructured":"Clements AN, Casillas AL, Flores CE, et al. Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. Cancer Immunol Res. 2025.","DOI":"10.1158\/2326-6066.CIR-24-0591"},{"key":"644_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1517\/14712598.2012.665444","volume":"12","author":"T Robak","year":"2012","unstructured":"Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2012;12:503\u201315.","journal-title":"Expert Opin Biol Ther"},{"key":"644_CR54","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song Q, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20\u2009+\u2009B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11:3255.","journal-title":"Sci Rep"},{"key":"644_CR55","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical hodgkin lymphoma with the anti-PD-1, Tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34:533\u201342.","journal-title":"Leukemia"},{"key":"644_CR56","doi-asserted-by":"crossref","unstructured":"Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U et al. Safety and Efficacy of Glofitamab for Relapsed\/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Blood Adv. 2024;bloodadvances.2024014903.","DOI":"10.1182\/bloodadvances.2024014903"},{"key":"644_CR57","doi-asserted-by":"publisher","first-page":"e200374","DOI":"10.1212\/NXI.0000000000200374","volume":"12","author":"JR Dahl","year":"2025","unstructured":"Dahl JR, Weier A, Winter C, Hintze M, Rothhammer V, Tsaktanis T, et al. Modulator of VRAC current 1 is a potential target antigen in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200374.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"644_CR58","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an Anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of Poor-Prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267\u201380.","journal-title":"J Clin Oncol"},{"key":"644_CR59","first-page":"59","volume":"12","author":"A Goodrich","year":"2021","unstructured":"Goodrich A. Advanced practice perspectives on preventing and managing tumor Lysis syndrome and neutropenia in chronic lymphocytic leukemia. J Adv Pract Oncol. 2021;12:59\u201370.","journal-title":"J Adv Pract Oncol"},{"key":"644_CR60","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1177\/13524585221101138","volume":"28","author":"J Lycke","year":"2022","unstructured":"Lycke J, Svenningsson A. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: commentary. Mult Scler. 2022;28:1177\u20138.","journal-title":"Mult Scler"},{"key":"644_CR61","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/10428190902934944","volume":"50","author":"R Ram","year":"2009","unstructured":"Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy\u2013rare but there! Leuk Lymphoma. 2009;50:1083\u201395.","journal-title":"Leuk Lymphoma"},{"key":"644_CR62","doi-asserted-by":"crossref","unstructured":"Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D et al. A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2025;blood.2024026401.","DOI":"10.1182\/blood.2024026401"},{"key":"644_CR63","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"644_CR64","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s11864-022-00953-5","volume":"23","author":"J Wiedmeier-Nutor","year":"2022","unstructured":"Wiedmeier-Nutor J, Leis J. Chronic lymphocytic leukemia: chemotherapy free and other novel therapies including CAR T. Curr Treat Options Oncol. 2022;23:904\u201319.","journal-title":"Curr Treat Options Oncol"},{"key":"644_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/j.seminhematol.2023.01.002","volume":"60","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Gr\u00e9goire C, Oliveira B, Chung K, Melenhorst JJ. Challenges and opportunities of CAR T-cell therapies for CLL. Semin Hematol. 2023;60:25\u201333.","journal-title":"Semin Hematol"},{"key":"644_CR66","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12:7844\u201358.","journal-title":"Cancer Med"},{"key":"644_CR67","doi-asserted-by":"publisher","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai NCAR-T, Cell Therapy. Mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016.","journal-title":"Front Immunol"},{"key":"644_CR68","doi-asserted-by":"publisher","first-page":"e000471","DOI":"10.1136\/jitc-2019-000471","volume":"8","author":"V Mancikova","year":"2020","unstructured":"Mancikova V, Peschelova H, Kozlova V, Ledererova A, Ladungova A, Verner J, et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J Immunother Cancer. 2020;8:e000471.","journal-title":"J Immunother Cancer"},{"key":"644_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","volume":"9","author":"Z Yin","year":"2021","unstructured":"Yin Z, Zhang Y, Wang X. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark Res. 2021;9:58.","journal-title":"Biomark Res"},{"key":"644_CR70","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"key":"644_CR71","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"644_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41408-025-01236-6","volume":"15","author":"AS Kittai","year":"2025","unstructured":"Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, et al. Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J. 2025;15:23.","journal-title":"Blood Cancer J"},{"key":"644_CR73","doi-asserted-by":"crossref","unstructured":"Bock TJ, Colonne CK, Fiorenza S, Turtle CJ. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat Rev Clin Oncol. 2025.","DOI":"10.1038\/s41571-025-00992-5"},{"key":"644_CR74","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/curroncol29050293","volume":"29","author":"Z Todorovic","year":"2022","unstructured":"Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, et al. CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr Oncol. 2022;29:3647\u201357.","journal-title":"Curr Oncol"},{"key":"644_CR75","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56:2388\u2013e24079.","journal-title":"Immunity"},{"key":"644_CR76","doi-asserted-by":"publisher","first-page":"718621","DOI":"10.3389\/fimmu.2021.718621","volume":"12","author":"S Chandrasekaran","year":"2021","unstructured":"Chandrasekaran S, Funk CR, Kleber T, Paulos CM, Shanmugam M, Waller EK. Strategies to overcome failures in T-Cell immunotherapies by targeting PI3K-\u03b4 and -\u03b3. Front Immunol. 2021;12:718621.","journal-title":"Front Immunol"},{"key":"644_CR77","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","volume":"139","author":"CR Funk","year":"2022","unstructured":"Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, et al. PI3K\u03b4\/\u03b3 Inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139:523\u201337.","journal-title":"Blood"},{"key":"644_CR78","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"},{"key":"644_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"644_CR80","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117\u201327.","journal-title":"Blood"},{"key":"644_CR81","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O\u2019Brien M, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6:5774\u201385.","journal-title":"Blood Adv"},{"key":"644_CR82","doi-asserted-by":"publisher","first-page":"108763","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"K Misawa","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: requisites, rationales, and trials. Pharmacol Ther. 2025;266:108763.","journal-title":"Pharmacol Ther"},{"key":"644_CR83","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42:1319\u201325.","journal-title":"Cancer Cell"},{"key":"644_CR84","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"644_CR85","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430\u201342.","journal-title":"Blood"},{"key":"644_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"644_CR87","doi-asserted-by":"publisher","first-page":"1499731","DOI":"10.3389\/fimmu.2024.1499731","volume":"15","author":"C Yang","year":"2024","unstructured":"Yang C, You J, Wang Y, Chen S, Tang Y, Chen H, et al. TLS and immune cell profiling: Immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. Front Immunol. 2024;15:1499731.","journal-title":"Front Immunol"},{"key":"644_CR88","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.26113","volume":"96","author":"SJ Nagle","year":"2021","unstructured":"Nagle SJ, Murphree C, Raess PW, Schachter L, Chen A, Hayes-Lattin B, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021;96:455\u201361.","journal-title":"Am J Hematol"},{"key":"644_CR89","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","volume":"139","author":"J Gauthier","year":"2022","unstructured":"Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. 2022;139:3722\u201331.","journal-title":"Blood"},{"key":"644_CR90","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020;10:79.","journal-title":"Blood Cancer J"},{"key":"644_CR91","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, et al. Immune reconstitution and associated infections following Axicabtagene Ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106:978\u201386.","journal-title":"Haematologica"},{"key":"644_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","volume":"43","author":"LM Braun","year":"2025","unstructured":"Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025;43:269\u2013e29119.","journal-title":"Cancer Cell"},{"key":"644_CR93","doi-asserted-by":"publisher","first-page":"1519082","DOI":"10.3389\/fphar.2025.1519082","volume":"16","author":"T Yan","year":"2025","unstructured":"Yan T, Long M, Liu C, Zhang J, Wei X, Li F, et al. Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients. Front Pharmacol. 2025;16:1519082.","journal-title":"Front Pharmacol"},{"key":"644_CR94","doi-asserted-by":"crossref","unstructured":"Othus M, Patel SP, Chae YK, Dietrich E, Streicher H, Sharon E et al. First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors. J Natl Cancer Inst. 2024;djae297.","DOI":"10.1093\/jnci\/djae297"},{"key":"644_CR95","doi-asserted-by":"publisher","first-page":"1471072","DOI":"10.3389\/fcell.2024.1471072","volume":"12","author":"L Gockeln","year":"2024","unstructured":"Gockeln L, Wirsd\u00f6rfer F, Jendrossek V. CD73\/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies. Front Cell Dev Biol. 2024;12:1471072.","journal-title":"Front Cell Dev Biol"},{"key":"644_CR96","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s11886-024-02147-x","volume":"26","author":"MT Gamero","year":"2024","unstructured":"Gamero MT, Patel A, Storozynsky E. The good (Tumor Killing) and the bad (Cardiovascular Complications) of Immunologic checkpoint inhibitors. Curr Cardiol Rep. 2024;26:1487\u201398.","journal-title":"Curr Cardiol Rep"},{"key":"644_CR97","doi-asserted-by":"publisher","first-page":"1510053","DOI":"10.3389\/fimmu.2025.1510053","volume":"16","author":"Q Xu","year":"2025","unstructured":"Xu Q, Li X, Yuan Y, Liang G, Hu Z, Zhang W, et al. Development and validation of a nomogram for predicting immune-mediated colitis in lung cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study in China. Front Immunol. 2025;16:1510053.","journal-title":"Front Immunol"},{"key":"644_CR98","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","volume":"34","author":"M Asnani","year":"2020","unstructured":"Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202\u20137.","journal-title":"Leukemia"},{"key":"644_CR99","doi-asserted-by":"crossref","unstructured":"Tumuluru S, Godfrey JK, Cooper A, Yu J, Chen X, MacNabb B et al. Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025;blood.2024025355.","DOI":"10.1182\/blood.2024025355"},{"key":"644_CR100","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13:eabe7378.","journal-title":"Sci Transl Med"},{"key":"644_CR101","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Zebley CC, Petersen CT, Fan Y, Anido AA, Yi Z, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13:eabh0272.","journal-title":"Sci Transl Med"},{"key":"644_CR102","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s43018-023-00604-0","volume":"4","author":"THH Coorens","year":"2023","unstructured":"Coorens THH, Collord G, Treger TD, Adams S, Mitchell E, Newman B, et al. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy. Nat Cancer. 2023;4:1095\u2013101.","journal-title":"Nat Cancer"},{"key":"644_CR103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14:161.","journal-title":"J Hematol Oncol"},{"key":"644_CR104","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419\u201331.","journal-title":"Nat Med"},{"key":"644_CR105","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31:3146\u201362.","journal-title":"Mol Ther"},{"key":"644_CR106","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"644_CR107","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","volume":"13","author":"Y Yang","year":"2024","unstructured":"Yang Y, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13:110.","journal-title":"Exp Hematol Oncol"},{"key":"644_CR108","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/2589977515666230220092125","volume":"15","author":"R Sharma","year":"2023","unstructured":"Sharma R, Suravarjhula L, Banerjee M, Kumar G, Kumar N. Chimeric antigen receptor T-cell therapy in cancer: A critical review. Curr Drug Res Rev. 2023;15:241\u201361.","journal-title":"Curr Drug Res Rev"},{"key":"644_CR109","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-X, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.","journal-title":"J Exp Clin Cancer Res"},{"key":"644_CR110","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"644_CR111","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","volume":"24","author":"M Gurney","year":"2022","unstructured":"Gurney M, O\u2019Reilly E, Corcoran S, Brophy S, Krawczyk J, Otto NM, et al. Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells. Cytotherapy. 2022;24:1087\u201394.","journal-title":"Cytotherapy"},{"key":"644_CR112","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"644_CR113","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994\u20132007.","journal-title":"Nat Immunol"},{"key":"644_CR114","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"644_CR115","doi-asserted-by":"publisher","first-page":"REVIEWS3014","DOI":"10.1186\/gb-2001-2-12-reviews3014","volume":"2","author":"JA Trapani","year":"2001","unstructured":"Trapani JA. Granzymes: a family of lymphocyte granule Serine proteases. Genome Biol. 2001;2:REVIEWS3014.","journal-title":"Genome Biol"},{"key":"644_CR116","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","volume":"27","author":"LN Kerbauy","year":"2021","unstructured":"Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, et al. Combining AFM13, a bispecific CD30\/CD16 antibody, with Cytokine-Activated blood and cord blood-Derived NK cells facilitates CAR-like responses against CD30\u2009+\u2009Malignancies. Clin Cancer Res. 2021;27:3744\u201356.","journal-title":"Clin Cancer Res"},{"key":"644_CR117","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10:12.","journal-title":"Biomark Res"},{"key":"644_CR118","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.3390\/cancers13215418","volume":"13","author":"L Herrera","year":"2021","unstructured":"Herrera L, Santos S, Vesga MA, Carrascosa T, Garcia-Ruiz JC, P\u00e9rez-Mart\u00ednez A, et al. The race of CAR therapies: CAR-NK cells for fighting B-Cell hematological cancers. Cancers (Basel). 2021;13:5418.","journal-title":"Cancers (Basel)"},{"key":"644_CR119","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi Y, Hao D, Qian H, Tao Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials. Exp Hematol Oncol. 2024;13:101.","journal-title":"Exp Hematol Oncol"},{"key":"644_CR120","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11427-015-4970-9","volume":"58","author":"Y Li","year":"2015","unstructured":"Li Y, Yin J, Li T, Huang S, Yan H, Leavenworth J, et al. NK cell-based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci. 2015;58:1233\u201345.","journal-title":"Sci China Life Sci"},{"key":"644_CR121","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10:318.","journal-title":"Cell Death Discov"},{"key":"644_CR122","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"644_CR123","doi-asserted-by":"crossref","unstructured":"Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.","DOI":"10.1056\/NEJMoa1910607"},{"key":"644_CR124","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13287-021-02251-7","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Rahman HS, Thangavelu L, Dorofeev A, Bayas-Morej\u00f3n F, Shirafkan N, et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther. 2021;12:200.","journal-title":"Stem Cell Res Ther"},{"key":"644_CR125","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193:216\u201330.","journal-title":"Br J Haematol"},{"key":"644_CR126","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"644_CR127","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"644_CR128","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"key":"644_CR129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25:102\u201316.","journal-title":"Nat Immunol"},{"key":"644_CR130","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.eururo.2021.01.025","volume":"79","author":"M Santoni","year":"2021","unstructured":"Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. Re: human chimeric antigen receptor macrophages for cancer immunotherapy. Eur Urol. 2021;79:887\u20139.","journal-title":"Eur Urol"},{"key":"644_CR131","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86.","journal-title":"Biomark Res"},{"key":"644_CR132","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.","journal-title":"Biomed Pharmacother"},{"key":"644_CR133","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467\u201380.","journal-title":"Blood"},{"key":"644_CR134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14:75.","journal-title":"J Hematol Oncol"},{"key":"644_CR135","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2022.22.e4","volume":"22","author":"D Moon","year":"2022","unstructured":"Moon D, Tae N, Park Y, Lee S-W, Kim DH. Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody. Immune Netw. 2022;22:e4.","journal-title":"Immune Netw"},{"key":"644_CR136","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"644_CR137","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","volume":"98","author":"R Wong","year":"2013","unstructured":"Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 2013;98:1930\u20138.","journal-title":"Haematologica"},{"key":"644_CR138","doi-asserted-by":"publisher","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","volume":"5","author":"EM McWilliams","year":"2016","unstructured":"McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, et al. Therapeutic CD94\/NKG2A Blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016;5:e1226720.","journal-title":"Oncoimmunology"},{"key":"644_CR139","doi-asserted-by":"publisher","first-page":"e1211220","DOI":"10.1080\/2162402X.2016.1211220","volume":"5","author":"M Vyas","year":"2016","unstructured":"Vyas M, Schneider A-C, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, et al. Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. Oncoimmunology. 2016;5:e1211220.","journal-title":"Oncoimmunology"},{"key":"644_CR140","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2013-07-512137","volume":"123","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, et al. A phase 1 study evaluating the safety and tolerability of Otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014;123:1302\u20138.","journal-title":"Blood"},{"key":"644_CR141","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41375-018-0249-z","volume":"33","author":"K Klupsch","year":"2019","unstructured":"Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, et al. COVA4231, a potent CD3\/CD33 bispecific fynomab with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. Leukemia. 2019;33:805\u20138.","journal-title":"Leukemia"},{"key":"644_CR142","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22:951\u2013e9593.","journal-title":"Cell Stem Cell"},{"key":"644_CR143","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao J, Guo X, Song Y. CD20 \u00d7 CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023;16:90.","journal-title":"J Hematol Oncol"},{"key":"644_CR144","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593\u2013605.","journal-title":"Lancet Haematol"},{"key":"644_CR145","doi-asserted-by":"publisher","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","volume":"7","author":"LL Sun","year":"2015","unstructured":"Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7:287ra70.","journal-title":"Sci Transl Med"},{"key":"644_CR146","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bbrc.2016.03.124","volume":"473","author":"C-Y Lu","year":"2016","unstructured":"Lu C-Y, Chen GJ, Tai P-H, Yang Y-C, Hsu Y-S, Chang M, et al. Tetravalent anti-CD20\/CD3 bispecific antibody for the treatment of B cell lymphoma. Biochem Biophys Res Commun. 2016;473:808\u201313.","journal-title":"Biochem Biophys Res Commun"},{"key":"644_CR147","first-page":"e5","volume":"32","author":"Y Li","year":"2025","unstructured":"Li Y, Li C, Lv K, Wang S, Li F. Efficacy and safety of ibrutinib as monotherapy or combination therapy in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): A systematic review and Meta-analysis. Am J Ther. 2025;32:e5\u201316.","journal-title":"Am J Ther"},{"key":"644_CR148","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653\u201362.","journal-title":"Leukemia"},{"key":"644_CR149","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"644_CR150","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cancers17020282","volume":"17","author":"A Bangolo","year":"2025","unstructured":"Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A, et al. Comprehensive review of early and late toxicities in CAR T-Cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel). 2025;17:282.","journal-title":"Cancers (Basel)"},{"key":"644_CR151","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"M-E Goebeler","year":"2024","unstructured":"Goebeler M-E, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539\u201360.","journal-title":"Nat Rev Clin Oncol"},{"key":"644_CR152","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838\u201347.","journal-title":"Drug Discov Today"},{"key":"644_CR153","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1080\/08820139.2022.2131569","volume":"51","author":"M Long","year":"2022","unstructured":"Long M, Mims AS, Li Z. Factors affecting the cancer immunotherapeutic efficacy of T cell bispecific antibodies and strategies for improvement. Immunol Invest. 2022;51:2176\u2013214.","journal-title":"Immunol Invest"},{"key":"644_CR154","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","volume":"4","author":"RE Kontermann","year":"2012","unstructured":"Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4:182\u201397.","journal-title":"MAbs"},{"key":"644_CR155","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","volume":"372","author":"U Brinkmann","year":"2021","unstructured":"Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372:916\u20137.","journal-title":"Science"},{"key":"644_CR156","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169:389\u201399.","journal-title":"Immunology"},{"key":"644_CR157","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790\u2013802.","journal-title":"Blood"},{"key":"644_CR158","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/blood.2022018081","volume":"140","author":"D M\u00fcller","year":"2022","unstructured":"M\u00fcller D. Optimized CD19\/CD22\/CD3 antibody. Blood. 2022;140:1750\u20131.","journal-title":"Blood"},{"key":"644_CR159","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254\u201362.","journal-title":"Lancet Oncol"},{"key":"644_CR160","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.","journal-title":"Pharmacol Ther"},{"key":"644_CR161","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"644_CR162","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346.","journal-title":"Protein Cell"},{"key":"644_CR163","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Sig Transduct Target Ther. 2022;7:93.","journal-title":"Sig Transduct Target Ther"},{"key":"644_CR164","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","volume":"69","author":"AG Polson","year":"2009","unstructured":"Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358\u201364.","journal-title":"Cancer Res"},{"key":"644_CR165","first-page":"2075","volume":"141","author":"P Harker-Murray","year":"2023","unstructured":"Harker-Murray P, Mauz-K\u00f6rholz C, Leblanc T, Mascarin M, Michel G, Cooper S, et al. Nivolumab and Brentuximab Vedotin with or without Bendamustine for R\/R hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023;141:2075\u201384.","journal-title":"Blood"},{"key":"644_CR166","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"L-M Fornecker","year":"2023","unstructured":"Fornecker L-M, Lazarovici J, Aurer I, Casasnovas R-O, Gac A-C, Bonnet C, et al. Brentuximab Vedotin plus AVD for First-Line treatment of Early-Stage unfavorable hodgkin lymphoma (BREACH): A multicenter, Open-Label, randomized, phase II trial. J Clin Oncol. 2023;41:327\u201335.","journal-title":"J Clin Oncol"},{"key":"644_CR167","doi-asserted-by":"publisher","first-page":"8731","DOI":"10.3390\/ijms24108731","volume":"24","author":"M Nakashima","year":"2023","unstructured":"Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-Cell leukemia\/lymphoma. Int J Mol Sci. 2023;24:8731.","journal-title":"Int J Mol Sci"},{"key":"644_CR168","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of Brentuximab Vedotin for hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"644_CR169","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"key":"644_CR170","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"key":"644_CR171","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","volume":"78","author":"B Xu","year":"2022","unstructured":"Xu B. Loncastuximab Tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Eur J Clin Pharmacol. 2022;78:707\u201319.","journal-title":"Eur J Clin Pharmacol"},{"key":"644_CR172","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab Tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"644_CR173","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.3390\/ijms25147580","volume":"25","author":"LM Ju\u00e1rez-Salcedo","year":"2024","unstructured":"Ju\u00e1rez-Salcedo LM, Nimkar S, Coraz\u00f3n AM, Dalia S. Loncastuximab Tesirine in the treatment of relapsed or refractory diffuse large B-Cell lymphoma. Int J Mol Sci. 2024;25:7580.","journal-title":"Int J Mol Sci"},{"key":"644_CR174","first-page":"1184","volume":"109","author":"PF Caimi","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab Tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109:1184\u201393.","journal-title":"Haematologica"},{"key":"644_CR175","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab Ozogamicin for de Novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139.","journal-title":"Haematologica"},{"key":"644_CR176","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of Gemtuzumab Ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"644_CR177","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie J-N, et al. Effect of Gemtuzumab Ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508\u201316.","journal-title":"Lancet"},{"key":"644_CR178","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"644_CR179","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab Ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"644_CR180","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78:1763\u20137.","journal-title":"Drugs"},{"key":"644_CR181","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","volume":"3","author":"AY Lin","year":"2019","unstructured":"Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Adv. 2019;3:2905\u201310.","journal-title":"Blood Adv"},{"key":"644_CR182","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab Mafodotin: first approval. Drugs. 2020;80:1607\u201313.","journal-title":"Drugs"},{"key":"644_CR183","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Mateos M-V. Belantamab Mafodotin, bortezomib, and dexamethasone for multiple myeloma. Reply. N Engl J Med. 2024;391:1364\u20135.","journal-title":"N Engl J Med"},{"key":"644_CR184","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.26586","volume":"97","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang X, Zhou Z, Liu Y, Yu L, Jia L, et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022;97:992\u20131004.","journal-title":"Am J Hematol"},{"key":"644_CR185","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3184\/003685002783238762","volume":"85","author":"ZW Chen","year":"2002","unstructured":"Chen ZW. Comparative biology of gamma delta T cells. Sci Prog. 2002;85:347\u201358.","journal-title":"Sci Prog"},{"key":"644_CR186","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev.immunol.14.1.511","volume":"14","author":"YH Chien","year":"1996","unstructured":"Chien YH, Jores R, Crowley MP. Recognition by gamma\/delta T cells. Annu Rev Immunol. 1996;14:511\u201332.","journal-title":"Annu Rev Immunol"},{"key":"644_CR187","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345.","journal-title":"Nat Med"},{"key":"644_CR188","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos B, Mensurado S, Coffelt SB. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019;19:392\u2013404.","journal-title":"Nat Rev Cancer"},{"key":"644_CR189","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen Receptor-Engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26:354\u201365.","journal-title":"Mol Ther"},{"key":"644_CR190","doi-asserted-by":"publisher","first-page":"1140623","DOI":"10.3389\/fimmu.2023.1140623","volume":"14","author":"L Ma","year":"2023","unstructured":"Ma L, Feng Y, Zhou Z. A close look at current \u0393\u03b4 T-cell immunotherapy. Front Immunol. 2023;14:1140623.","journal-title":"Front Immunol"},{"key":"644_CR191","first-page":"1643","volume":"31","author":"T Ebina","year":"2004","unstructured":"Ebina T. [Life-prolonging effect of Immunocell BAK (BRM activated killer) therapy\u2013evidence based integrative medicine]. Gan Kagaku Ryoho. 2004;31:1643\u20135.","journal-title":"Gan Kagaku Ryoho"},{"key":"644_CR192","first-page":"1339","volume":"64","author":"T Ebina","year":"2006","unstructured":"Ebina T. [Non-small cell lung cancer\u2013immunocell BAK (BRM activated killer) therapy]. Nihon Rinsho. 2006;64:1339\u201344.","journal-title":"Nihon Rinsho"},{"key":"644_CR193","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/A:1008047628284","volume":"11","author":"T Ebina","year":"1998","unstructured":"Ebina T, Fujimiya Y, Yamaguchi T, Ogama N, Sasaki H, Isono N, et al. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Biotherapy. 1998;11:241\u201353.","journal-title":"Biotherapy"},{"key":"644_CR194","first-page":"1507","volume":"40","author":"T Ebina","year":"2013","unstructured":"Ebina T. [Local injection of BRM-activated killer cells into an abdominal wall tumor]. Gan Kagaku Ryoho. 2013;40:1507\u20139.","journal-title":"Gan Kagaku Ryoho"},{"key":"644_CR195","first-page":"1812","volume":"39","author":"T Ebina","year":"2012","unstructured":"Ebina T. [Hepatic intra-arterial infusion of biological response modifier (BRM)-activated killer immune lymphocytes to treat liver cancer]. Gan Kagaku Ryoho. 2012;39:1812\u20134.","journal-title":"Gan Kagaku Ryoho"},{"key":"644_CR196","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1348-0421.2001.tb02638.x","volume":"45","author":"T Ebina","year":"2001","unstructured":"Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells. Microbiol Immunol. 2001;45:403\u201311.","journal-title":"Microbiol Immunol"},{"key":"644_CR197","first-page":"1230","volume":"30","author":"I Urushizaki","year":"1989","unstructured":"Urushizaki I. [Therapy by biological response modifiers]. Rinsho Ketsueki. 1989;30:1230\u20132.","journal-title":"Rinsho Ketsueki"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00644-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:48:10Z","timestamp":1744278490000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00644-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00644-5","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}